一线纳武利尤单抗联合伊匹木单抗对比舒尼替尼治疗转移性肾细胞癌的成本效果分析
该研究基于CheckMate 214三期随机临床试验(1096例患者,中位年龄62岁)构建Markov模型,从美国支付方角度评估纳武利尤单抗联合伊匹木单抗对比舒尼替尼一线治疗中高危转移性肾细胞癌的终生成本与效果。结果显示联合方案额外获得0.96个质量调整生命年(QALY),每QALY成本为108363美元,在10万至15万美元/QALY的支付意愿阈值下具有成本效果。
要点
- 纳武利尤单抗联合伊匹木单抗较舒尼替尼额外获得0.96个QALY,每QALY成本108363美元。
- 在10万至15万美元/QALY支付意愿阈值下,联合方案对中高危转移性肾细胞癌具有成本效果。
- 亚组分析显示PD-L1表达≥1%的患者联合方案最具成本效果,每QALY成本86390美元。
核心结论
- 在该模型中,对于中高危转移性肾细胞癌患者,纳武利尤单抗联合伊匹木单抗对比舒尼替尼在每QALY 10万至15万美元的支付意愿阈值下估计具有成本效果。
研究设计与样本
- 基于CheckMate 214三期随机临床试验(纳入1096例转移性肾细胞癌患者,中位年龄62岁)构建Markov模型,从美国支付方角度比较纳武利尤单抗联合伊匹木单抗与舒尼替尼一线治疗的终生成本和效果。
- 模型中患者接受舒尼替尼或纳武利尤单抗联合伊匹木单抗4剂后序贯纳武利尤单抗单药治疗。
- 主要结局为生命年、质量调整生命年(QALY)和终生成本,支付意愿阈值为每QALY 10万至15万美元,并进行单因素、双因素和概率敏感性分析及亚组分析。
主要发现
- 纳武利尤单抗联合伊匹木单抗较舒尼替尼额外获得0.96个QALY,每QALY成本为108363美元。
- 敏感性分析显示结果对总生存风险比(0.63;95%CI 0.44-0.89)和患者平均体重(70 kg,范围40-200 kg)最敏感。
- 纳武利尤单抗联合伊匹木单抗的成本(均值32213.44美元;范围25770.75-38656.13美元)、效用值(均值0.82;范围0.65-0.98)及舒尼替尼组接受纳武利尤单抗的比例(均值0.27;范围0.22-0.32)对模型结果影响中等或较小。
- 亚组分析显示,PD-L1表达≥1%的患者联合方案最具成本效果,每QALY成本为86390美元。
关键数值与推荐
- 增量成本效果比为每QALY 108363美元,额外获得0.96个QALY。
- 总生存风险比为0.63(95%CI 0.44-0.89)。
- PD-L1表达≥1%亚组每QALY成本为86390美元。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recently, new drugs have been approved for the first-line treatment of metastatic renal cell carcinoma (mRCC). Nivolumab plus ipilimumab significantly increases overall survival for intermediate- and poor-risk patients with mRCC. However, considering the high cost of nivolumab plus ipilimumab, there is a need to assess its value by considering both efficacy and cost. OBJECTIVE: To evaluate the cost-effectiveness of nivolumab plus ipilimumab vs sunitinib in the first-line setting for intermediate- and poor-risk patients with mRCC from the US payer perspective. DESIGN, SETTING, AND PARTICIPANTS: A Markov model was developed to compare the lifetime cost and effectiveness of nivolumab plus ipilimumab vs sunitinib in the first-line treatment of mRCC using outcomes data from the CheckMate 214 phase 3 randomized clinical trial, which included 1096 patients with mRCC (median age, 62 years) and compared nivolumab plus ipilimumab vs sunitinib as first-line treatment of mRCC. In the analysis, patients were modeled to receive sunitinib or nivolumab plus ipilimumab for 4 doses followed by nivolumab monotherapy. MAIN OUTCOMES AND MEASURES: Life-years, quality-adjusted life-years (QALYs), and lifetime costs were estimated, at a willingness-to-pay threshold of $100 000 to $150 000 per QALY. Univariable, 2-way, and probabilistic sensitivity analyses were performed to evaluate the model uncertainty. Additional subgroup analyses were performed. RESULTS: Nivolumab plus ipilimumab provided an additional 0.96 QALYs, at a cost of $108 363 per QALY. Sensitivity analyses found the results to be most sensitive to overall survival hazard ratio (0.63; 95% CI, 0.44-0.89) and mean patient weight (70 kg, range, 40-200 kg). Other variables, such as the cost of nivolumab plus ipilimumab (mean, $32 213.44; range, $25 770.75-$38 656.13), utility values for nivolumab plus ipilimumab (mean, 0.82; range, 0.65-0.98), and proportion receiving nivolumab in sunitinib arm (mean, 0.27; range, 0.22-0.32), had a moderate or minor influence on model results. Subgroup analyses demonstrated that nivolumab plus ipilimumab was most cost-effective for patients with programmed cell death 1 ligand 1 expression of at least 1% ($86 390 per QALY). CONCLUSIONS AND RELEVANCE: In this model, nivolumab plus ipilimumab was estimated to be cost-effective compared with sunitinib for intermediate- and poor-risk patients with mRCC at a willingness-to-pay threshold from $100 000 to $150 000 per QALY.
引用
- Wan X, Zhang Y, Tan C, et al. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis. JAMA Oncol. 2019. PMID: 30789633. doi:10.1001/jamaoncol.2018.7086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。